FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. (Source: World Pharma News)
Source: World Pharma News - July 18, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Excelera ® Specialty Pharmacy Network Announces Access to Breast...
The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15575484.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 17, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer Trastuzumab Increases PFS in Women With HER2/neu Uterine Cancer
This well-done study should prompt oncologists to consider adding trastuzumab to carboplatin-paclitaxel treatment for women with advanced HER2/neu-positive uterine cancer, says Dr Maurie Markman.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
(University of Colorado Anschutz Medical Campus) Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 10, 2018 Category: Cancer & Oncology Source Type: news

ASCO Updates Guideline on Management of HER2-Positive Breast Cancer
An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

ASCO Updates Clinical Guidelines for HER2+ Breast Cancer ASCO Updates Clinical Guidelines for HER2+ Breast Cancer
ASCO has updated its 2014 guidelines for systemic treatment of HER2+ breast cancer and also for brain metastases but did not change the recommendations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine's July featured article of the month. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2018 Category: Cancer & Oncology Source Type: news

TRBV Gene Use Could Act as Biomarker in HER2+ Breast Cancer
Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

New immunotherapy trial for children with central nervous system tumors opens
(Seattle Children's) Seattle Children's has opened a pioneering chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory HER2-positive central nervous system (CNS) tumors where CAR T cells will be delivered directly into the brain. In the phase I trial, BrainChild-01, cancer-fighting CAR T cells will be infused through a catheter, either into the cavity where the tumor has been removed or the CNS ventricular system, depending on the location of the tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 19, 2018 Category: Cancer & Oncology Source Type: news

Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 Inhibitor
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Authors: Robert Doebele, MD Source Type: news

A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes. (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2018 Category: Cancer & Oncology Authors: Ericson Stoen, MD, Peter Kabos, MD, Kelly C. Borden, MD, Regina J. Brown, MD, Virginia F. Borges, MD, MMSc, Jennifer R. Diamond, MD Source Type: news

NICE Rejects Adjuvant Perjeta in HER2 Breast Cancer
(MedPage Today) -- In contrast with FDA, Britain's cost watchdog says drug may not offer'meaningful'benefit (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 15, 2018 Category: American Health Source Type: news

Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer
Safety, efficacy and clinical outcomes were similar for Amgen's trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Living With Cancer: Understanding HER2-positive breast cancer
HER2-positive breast cancer? HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. While HER2-positive breast cancers tend to be more aggressive than other types of breast cancer, treatments that specifically target it are effective, and the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 8, 2018 Category: Databases & Libraries Source Type: news

Adding Abemaciclib Offers Good Outcomes in Pre-/Perimenopausal Breast Cancer
Dave LevitanJun 5, 2018The addition of abemaciclib to fulvestrant significantly improved PFS and time to subsequent chemotherapy in pre- and perimenopausal HR-positive/HER2-negative breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO: Endocrine Tx Noninferior for HR + , HER2 − Breast Cancer
Similar efficacy for endocrine, chemoendocrine tx for women with midrange 21 - gene recurrence score (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Conference News, Source Type: news

ASCO: Endocrine Tx Noninferior for HR & #43;, HER2 & #8722; Breast Cancer
MONDAY, June 4, 2018 -- For women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer with a midrange 21-gene recurrence score, adjuvant endocrine therapy is noninferior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

ASCO & NEJM: AI plus ovarian suppression yields benefit in high-risk younger breast cancer patients
(Dana-Farber Cancer Institute) Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

NCI-MATCH precision medicine clinical trial releases new findings
(ECOG-ACRIN Cancer Research Group) The released data is from three treatment arms, all single-arm phase 2 studies: the drug taselisib in patients with mutations in the PIK3CA gene (Arm I); the drug ado-trastuzumab emtansine (T-DM1) in patients with HER2-overexpressing tumors (Arm Q); and the drug AZD4547 in patients with mutations in the FGFR pathway (Arm W). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Adding Ribociclib Improves PFS in Premenopausal Breast Cancer
Dave LevitanJun 1, 2018Ribociclib plus endocrine therapy resulted in improved progression-free survival in premenopausal women with HR-positive, HER2-negative advanced breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2018 Category: Cancer & Oncology Authors: A Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 1, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab for 6 Months Instead of 1 Year? Trastuzumab for 6 Months Instead of 1 Year?
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab Emtansine in HER2 Metastatic Breast Cancer Trastuzumab Emtansine in HER2 Metastatic Breast Cancer
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
(American Society of Clinical Oncology) A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

Targeting AXL Could Slow Metastasis in HER2-Positive Breast Cancer
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Lab Study Shows HER2 Inhibitor Lapatinib Can Induce Cell Proliferation
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news

Delay to Formalin Fixation Effect on Breast Cancer Molecules Delay to Formalin Fixation Effect on Breast Cancer Molecules
What effect does delay to formalin fixation have on breast biomarkers such as ER, PR, HER2, Ki-67, and others? Might DFF be a confounding factor in breast biomarker assays?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)
(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2018 Category: Hematology Source Type: news

HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Herceptin, trastuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator ... Biopharmaceuticals, Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, trastuzumab, Herceptin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event HER2 Is Not a Cancer Subtype but Rather a Pan-Cancer Event
Research in breast cancer genomics reveals the potential for combining anti-HER2 therapy with anti-androgen agents.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Protecting Breast Cancer Patients From Cardiac Adverse Effects of Treatment With Anthracyclines and HER2-Targeted Therapies
During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: Jean-Bernard Durand, MD Tags: Conference Report Conferences/MBCC Source Type: news

Why Some Breast Cancer Becomes Resistant to Hormone Therapy Why Some Breast Cancer Becomes Resistant to Hormone Therapy
Acquired mutations in HER2 explain some of the resistance to hormone therapy seen in metastatic breast cancer; this unexpected finding offers a way to clinically manage these patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Management of Early-Stage HER2-Positive Breast Cancer
During the 2018 Miami Breast Cancer Conference, Dr. Sara Hurvitz discussed current management options for patients with early-stage HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2018 Category: Cancer & Oncology Authors: Sara Hurvitz, MD Tags: Conferences/MBCC News Source Type: news

Area surrounding a tumor impacts how breast cancer cells grow
(Oregon Health& Science University) A research team from Oregon Health& Science University, led by Joe Gray, Ph.D. and Jim Korkola, Ph.D. discover a tumor's 'microenvironment' plays a critical role in how HER2 positive breast cancer responds to treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2018 Category: International Medicine & Public Health Source Type: news

Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer
Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news